<DOC>
	<DOCNO>NCT01931202</DOCNO>
	<brief_summary>This project seek elucidate mechanism antidepressant medication limit efficacy Late Life Depression ( LLD ) order develop new treatment intervention prevalent disable illness . We hypothesize presence executive dysfunction ( ED ) , common depress adult 60 , impairs ability form appropriate expectancy improvement antidepressant treatment . Greater expectancy show improve antidepressant treatment outcome hypothesize primary mechanism placebo effect . Moreover , white matter hyperintensities ( WMH ) magnetic resonance imaging ( MRI ) prevalent patient LLD compare healthy control . It argue WMH contribute pathogenesis LLD ED decrease efficacy antidepressant medication disrupt connection prefrontal cortical ( PFC ) subcortical structure . Vascular lesion white matter tract may also compromise pathway expectancy-based placebo effect influence depressive symptom . Expectancies reflect activation PFC area may improve depressive symptom modulate activity subcortical region subserve negative affective system ( i.e. , amygdala ) well important reward hedonic capacity ( nucleus accumbens ventral striatum ) . Thus , LLD patient withED WMH may sustain `` double-hit '' ability experience placebo effect antidepressant treatment : ED diminish ability generate appropriate treatment expectancy , WMH disrupt physiologic pathway expectancy lead improvement depressive symptom .</brief_summary>
	<brief_title>Mechanisms Antidepressant Non-Response Late-Life Depression</brief_title>
	<detailed_description>To determine whether decreased antidepressant medication response LLD patient ED WMH cause loss expectancy effect , evaluate 130 outpatient LLD baseline determine degree ED ( interference score Stroop Color-Word Test ) , WMH burden ( severity score Fazekas modify Coffey Rating Scale derive anatomical MRI ) , white matter tract integrity ( use diffusion tensor image [ DTI ] ) . Building work K23 Award , manipulate participant ' expectancy improvement 8-week duration antidepressant trial randomize open administration escitalopram ( i.e. , high expectancy ) placebo-controlled administration escitalopram ( i.e. , low expectancy ) . The difference antidepressant response observe open placebo-controlled medication treatment measure expectancy contribution outcome , substantial young depressed adult hypothesize diminished LLD patient ED WMH .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men woman age 6090 year Diagnosis nonpsychotic Diagnostic Statistical Manual ( DSM ) IV MDD 24item Hamilton Rating Scale Depression ( HRSD ) score â‰¥ 16 Willing capable providing inform consent comply study procedure Current comorbid Axis I DSM IV disorder Nicotine Dependence , Adjustment Disorder , Anxiety Disorder diagnosis substance abuse dependence ( exclude Nicotine Dependence ) within past 12 month History psychosis , psychotic disorder , mania , bipolar disorder Diagnosis probable Alzheimer 's Disease , Vascular Dementia , Parkinson 's Disease MMSE &lt; 24 HRSD suicide item &gt; 2 Clinical Global Impressions ( CGI ) Severity score 7 baseline history allergic adverse reaction escitalopram , nonresponse adequate trial escitalopram ( least 4 week dose 20mg ) current episode current treatment psychotherapy , antidepressant , antipsychotic , mood stabilizer contraindication MRI scanning ( metal body ) unable tolerate scanning procedure ( i.e. , severe obesity , claustrophobia ) acute , severe , unstable medical neurological illness</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>